A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer
Sponsor: Mabscale, LLC
This PHASE3 trial investigates Non-Small Cell Lung Cancer and is currently actively recruiting participants. Mabscale, LLC leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
May 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mabscale, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Ivanovo, Russia , Kaluga, Russia , Kazan', Russia , Moscow, Russia , Murmansk, Russia , Nizhny Novgorod, Russia , Novosibirsk, Russia , Omsk, Russia , Perm, Russia and 9 more locations